Melinta Therapeutics, Inc.
Case Number:
1:19-bk-12748
Court:
Nature of Suit:
Firms
- Chiesa Shahinian
- Chipman Brown
- Cole Schotz
- Connolly Gallagher
- Faegre Drinker
- Ford & Paulekas
- Fox Rothschild
- Garfunkel Wild
- Gellert Scali
- Herrick Feinstein
- Hogan McDaniel
- Landis Rath
- Law Office of Susan E. Kaufman
- Margolis Edelstein
- Marshall Dennehey
- Maurice Wutscher
- McGlinchey Stafford
- Miller Nash LLP
- Morris James
- Nelson Mullins
- Pachulski Stang
- Paul Weiss
- Porzio Bromberg
- Potter Anderson
- Powell Firm
- Ropes & Gray
- Skadden Arps
- Smith Katzenstein
- Squire Patton
- Sullivan & Cromwell
Companies
- Automotive Rentals Inc.
- Cardinal Health Inc.
- Eli Lilly & Co.
- McKesson Corp.
- Melinta Therapeutics Inc.
- Oracle Corp.
- Patheon Inc.
- The Medicines Co.
- The Scripps Research Institute
- Yale University
Government Agencies
Sectors & Industries:
-
July 07, 2020
Judge Finds No Fraud In Vote For Melinta's Ch. 11 Plan
Emphasizing that she found no fraud in vote-handling or counts prior to confirmation of antibiotic developer Melinta Therapeutics' Chapter 11 reorganization in April, a bankruptcy judge in Delaware declined Tuesday to reconsider a recent denial of stockholder requests to revoke the plan.
-
April 03, 2020
Melinta's Ch. 11 Exculpation Runs To Plan Date, Court Rules
A Delaware bankruptcy judge ruled Friday that the exculpation provisions in the Chapter 11 plan of antibiotic maker Melinta Therapeutics only apply until the court-approved plan becomes effective, limiting the length of the provision that was requested by the debtor.
-
April 02, 2020
Melinta Gets OK For Ch. 11 Equity Swap Plan With Creditor
Bankrupt antibiotic developer Melinta Therapeutics received court approval Thursday in Delaware for its proposed Chapter 11 debt-for-equity transaction that will see a secured creditor acquire the reorganized company in exchange for $140 million in debt relief.
-
March 30, 2020
US Trustee Says Melinta Plan Releases Go Too Far
The U.S. Trustee's Office is arguing to a Delaware bankruptcy judge that the legal liability releases in antibiotics maker Melinta Therapeutics Inc.'s proposed Chapter 11 "far exceed" what is allowed under Delaware case law.
-
March 13, 2020
Melinta Creditor Deal OK Clears Path To Ch. 11 Plan Approval
A restructuring support agreement that forms the basis of the Chapter 11 plan of pharmaceutical company Melinta Therapeutics Inc. received court approval Friday in Delaware bankruptcy court, paving the way for consensual confirmation of the plan next month.
-
February 21, 2020
Melinta's Ch. 11 Plan Docs Approved With New Information
Antibiotics maker Melinta Therapeutics Inc. received court approval Friday in Delaware for its Chapter 11 plan disclosure statement after the debtor agreed to add new information regarding its intent to substantively consolidate its estates for distribution purposes.
-
February 14, 2020
Melinta's Ch 11. Consolidation Is 'Unjustified,' Objectors Say
Bankrupt antibiotics maker Melinta Therapeutics Inc. received two objections Friday to its proposed Chapter 11 plan that seeks to substantively consolidate its various entities' debts for distributions to creditors, a move derided by a significant creditor and the U.S. trustee as unjustified.
-
February 10, 2020
Melinta Gets Nod For Ch. 11 Auction Starting At $140M
Ailing antibiotics developer Melinta Therapeutics Inc. appears to have secured approval for a previously contested Chapter 11 sale plan that allows top creditor Deerfield Management Co. to serve as the opening bidder with a $140 million credit bid at an upcoming auction.